BIO-MANGUINHOS ADALIMUMABE
119,90 R$
Prix max. consommateur (CMED)
Analogs of BIO-MANGUINHOS ADALIMUMABE
Find cheaper analogs and generic equivalents for BIO-MANGUINHOS ADALIMUMABE.
Principe actif : adalimumab
Aperçu du produit
About BIO-MANGUINHOS ADALIMUMABE
BIO-MANGUINHOS ADALIMUMABE is a medication containing the active ingredient Adalimumab, classified as Tumor Necrosis Factor Blocker. Adalimumab, sold under the brand name Humira and others, is a disease-modifying antirheumatic drug and monoclonal antibody used to treat rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and.
Key Benefits & Uses
- Used for: 1 INDICATIONS AND USAGE HYRIMOZ is a tumor necrosis factor (TNF)-blocker indicated for: • Reducing signs and symptoms, inducing major clinical.
- Use only as directed on the product label or by a healthcare professional.
- Follow the authorised product information for dosing and duration of use.
Active Ingredient & Action
Adalimumab, the active ingredient in BIO-MANGUINHOS ADALIMUMABE, belongs to the Tumor Necrosis Factor Blocker class. 1 INDICATIONS AND USAGE HYRIMOZ is a tumor necrosis factor (TNF)-blocker indicated for: • Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. ( 1. Inactive ingredients: not listed in source data.
Important Notes
Always read and follow the label instructions carefully before taking BIO-MANGUINHOS ADALIMUMABE. If you have any underlying medical conditions, are taking other medicines, or are pregnant or breastfeeding, consult a doctor or pharmacist before use. Do not exceed the recommended dose on the package and do not use BIO-MANGUINHOS ADALIMUMABE for extended periods without medical advice.
Visitor ratings
Help others by rating how useful this product page is.
No ratings yet — be the first.